Evidence map›Paper›PMID 31086662›Full record

ArticleBiomedical reports2019

Frequency of

Patricia Cuautle-Rodríguez, Nidia Rodríguez-Rivera, Fernando De Andrés, Fernando Castillo-Nájera, Adrián Llerena, Juan Arcadio Molina-Guarneros

Open access · diamondAbstract read
In one paragraph

Article in Biomedical reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Observational
  2. Article
  3. Review
  4. rs622342 inJournal of personalized medicine · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Patricia Cuautle-RodríguezDepartamento de Farmacología, Facultad de Medicina, Universidad Nacional Autónoma de México, Ciudad de México 04510, México.
Nidia Rodríguez-RiveraDepartamento de Farmacología, Facultad de Medicina, Universidad Nacional Autónoma de México, Ciudad de México 04510, México.
Fernando De AndrésCentro de Investigación Clínica Área de Badajoz, SES Hospital Universitario, Universidad de Extremadura, Badajoz 06071, Spain.
Fernando Castillo-NájeraCentro de Salud T‑III Portales, Servicios de Salud Gobierno de la Ciudad de México, Ciudad de México 03660, México.
Adrián LlerenaCentro de Investigación Clínica Área de Badajoz, SES Hospital Universitario, Universidad de Extremadura, Badajoz 06071, Spain.
Juan Arcadio Molina-GuarnerosDepartamento de Farmacología, Facultad de Medicina, Universidad Nacional Autónoma de México, Ciudad de México 04510, México.
Universidad de Extremadura · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The majority of Mexican patients with diabetes mellitus type 2 (DMT2) (67.9-85.0%) are prescribed sulphonylureas (SUs), which are metabolized by cytochrome P450 2C9 (abbreviated as

Indexed as

cytochrome P450 2C9diabetesglibenclamideglycated hemoglobin A1cmetformin

Identifiers

PMID31086662
PMCPMC6489535
OpenAlexW2926953916

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.